Leap Therapeutics Files 8-K Report
Ticker: CYPH · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Leap Therapeutics filed an 8-K, likely routine financial updates.
AI Summary
On October 6, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly Dekkun Corp, is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This 8-K filing indicates Leap Therapeutics is providing updates or submitting required financial documents to the SEC, which is standard corporate practice.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural update without immediate material news.
Key Numbers
- 001-37990 — SEC File Number (Identifies the company's filing with the SEC)
- 27-4412575 — EIN (Employer Identification Number for tax purposes)
Key Players & Entities
- Leap Therapeutics, Inc. (company) — Registrant
- Dekkun Corp (company) — Former company name
- October 6, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Principal executive office location
FAQ
What specific 'Other Events' are being reported by Leap Therapeutics, Inc. on October 6, 2025?
The provided text of the 8-K filing does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates the company is submitting required financial information and supporting documents to the SEC, which could include quarterly or annual reports, or other material financial disclosures.
When did Leap Therapeutics, Inc. change its name from Dekkun Corp?
The filing states the Date of Name Change was January 7, 2011.
Where is Leap Therapeutics, Inc.'s principal executive office located?
The principal executive office is located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
What is the Standard Industrial Classification (SIC) code for Leap Therapeutics, Inc.?
The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2025-10-06 09:08:18
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share LPTX The NASDAQ Capital Mar
Filing Documents
- tm2528058d1_8k.htm (8-K) — 24KB
- tm2528058d1_ex99-1.htm (EX-99.1) — 20KB
- tm2528058d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-096966.txt ( ) — 215KB
- lptx-20251006.xsd (EX-101.SCH) — 3KB
- lptx-20251006_lab.xml (EX-101.LAB) — 33KB
- lptx-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528058d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 6, 2025, Leap Therapeutics, Inc. (the "Company") issued a press release announcing a private placement and its adoption of a digital asset treasury strategy. The Company intends to continue to pursue its current line of business in addition to the pursuit of its digital asset treasury strategy. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 8.01 by reference. 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Date: October 6, 2025 /s/ Douglas E. Onsi Douglas E. Onsi President & CEO